skip to Main Content

Durvalumab With or Without Tremelimumab Yields Poor Activity in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Findings from a recent study of patients with metastatic pancreatic ductal adenocarcinoma showed that durvalumab therapy plus tremelimumab was well-tolerated but demonstrated poor activity and that durvalumab alone yielded no response (JAMA Oncol. 2019 Jul 18. Epub ahead of print).

 

“New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma…are needed,” asserted Eileen M. O’Reilly, MD, Gastrointestinal Medical Oncology, David M. Rubenstein Center for Pancreatic Cancer, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, and colleagues, who assessed the use of durvalumab therapy with or without tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. Read more . . . 


Back To Top